

May 15, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Press Release

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release of the Company for the Fourth Quarter and Year ended March 31, 2025.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Rudalf Corriea
Company Secretary and Compliance Officer

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com



Alivus Life Sciences Delivers Strong Q4FY25 Performance with 21% YoY Revenue Growth

EBITDA Margins at 32.1% YoY

Mumbai, May 15, 2025: Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced its financial results for the quarter and year ended March 31, 2025.

Revenue from operations for Q4FY25 reached Rs. 6,496 Mn, a growth of 21.1% YoY and 1.2% QoQ. For FY25, revenue from operations was Rs. 23,869 Mn, a growth of 4.5% YoY.

For Q4FY25, EBITDA was at Rs. 2,085 Mn, a growth of 44.2% YoY and 3.8% QoQ. EBITDA margins were at 32.1%, up 520 bps YoY and up 80 bps QoQ. EBITDA for FY25 was at Rs. 7,172 Mn while EBITDA margins stood at 30.0% as compared to 30.1% in FY24 despite the absence of PLI benefit in the current year.

PAT for the quarter stood at Rs. 1,419 Mn and PAT margins were at 21.8%. For FY25, the company recorded PAT of Rs. 4,857 Mn with PAT margins of 20.3%.

During FY25, the company generated a strong free cash flow of Rs. 2,328 Mn leading to Cash and Cash Equivalents (including short term investments) of Rs. 5,487 Mn as of 31 March 2025.

Commenting on the company's performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, *"FY25 was our first full year under the Nirma ownership. Our overall performance has remained consistent with past years, with sustained margins, despite facing external challenges, most notably the loss in PLI revenue. The road ahead has significant opportunities for which we have begun working in earnest via capacity investments and the integration of newer technologies into R&D and manufacturing operations.*

One of the most encouraging outcomes this year was our ability to maintain EBITDA margins at 30%, even in the absence of PLI benefits and amid market headwinds. This reflects the strength of our diversified portfolio and our continued focus on operational efficiency.

Our full-year sales grew by 7.1%, normalizing for the PLI benefit last year and backed by healthy contributions from both GPL and Non-GPL segments. As we move into FY26, we remain committed to delivering sustainable growth with stable margins, while continuing to invest in our core growth drivers, expanding our product pipeline, and scaling our operations to create long-term value."

Tushar Mistry, CFO, Alivus Life Sciences Limited said, *"We delivered strong revenue growth of 21.1% in Q4FY25, with 520 bps improvement in EBITDA margins at 32.1%. We concluded the year on a positive note, with full-year revenue growth of 7.1% normalised for PLI benefits, which has been in line with our earlier guidance.*

For FY25, both gross margins and EBITDA margins remained stable at ~55% and ~30% respectively, supported by a favourable product mix and cost discipline. Notably, we maintained EBITDA margins of 30% without PLI scheme benefits, a strong validation of our operational resilience.

Alivus Life Sciences has generated healthy cash flows of Rs. 233 Crore during the year, which supports our growth initiatives while enabling us to maintain a debt-free balance sheet."

PRESS RELEASE

For Immediate dissemination



Additional Highlights:

- DMF / CEP filings continue across major markets, taking the total cumulative filings to 561 as on 31 March 2025
- In Q4FY25, four synthetic small molecules were added to the development grid
- The HP API portfolio has 24 APIs in the active grid with seven products validated, five products in advanced stages of development and 12 products under lab development stage

Capex Update:

- Solapur – Phase 1 construction work is in progress for 200 KL capacity

About Alivus Life Sciences Ltd (ALIVUS)

Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 165 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on <https://www.alivus.com>

For any further queries please contact:

Soumi Rao | General Manager – Corporate Communications

Email: Soumi.Rao@glenmarklifesciences.com

Mobile: 98701 96931

Ernst & Young LLP – Investor Relations

Diwakar Pingle

Email: Diwakar.Pingle@in.ey.com

Runjhun Jain

Email: Runjhun.Jain1@in.ey.com

Sneha Salian

Email: Sneha2.Salian@in.ey.com